Alkermes Unveils Bydureon Royalties And Its Own Long-acting Form Of Lilly's Zyprexa
This article was originally published in The Pink Sheet Daily
Executive Summary
Risperdal Consta will be cash cow for years to come, but other drugs in pipeline will fill out revenue stream.
You may also be interested in...
Amylin Hit Hardest By Bydureon Setback
Amylin Pharmaceuticals, Eli Lilly, and Alkermes, will all feel the financial effects of the diabetes drug's delay to different degrees.
Amylin Hit Hardest By Bydureon Setback
Amylin Pharmaceuticals, Eli Lilly, and Alkermes, will all feel the financial effects of the diabetes drug's delay to different degrees.
FDA's "Complete Response" Letter For Byetta LAR Isn't Too Onerous, Amylin Says
Analysts still expect an approval and launch by year end of long-acting exenatide, now branded as Bydureon.